β-Lactam antimicrobials: What have you done for me lately?

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 76-83

  Talbot, George H ^a  

^a Bayview Asset Management   (United States)

Author keywords

Pipeline; Resistance; lactam; lactamase; lactamase inhibitor

Indexed keywords

BAL 30072; BAL 30376; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; SIDEROPHORE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHYSICIAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84872833161     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06809.x     Document Type: Article

References (92)

1. Fauci, A.S. & D.M. Morens 2012. 200th anniversary article: the perpetual challenge of infectious diseases. N. Engl. J. Med. 366: 454-461.
2. Infectious Diseases Society of America. 2003. Antibiotic-resistant infections increasingly common among healthy people [press release]. Alexandria, VA October 9, 2003.
3. Infectious Diseases Society of America. July 2004. Bad bugs, no drugs. as antibiotic discovery stagnates ... a public health crisis brews. Available at: http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10x20/Images/Bad%20Bugs%20no%20Drugs.pdf. Accessed 3 July 2012.
4. Talbot, G.H., J. Bradley, J.E. Edwards, et al. 2006. Bad bugs need drugs: what's in the development pipeline? an update from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42: 657-668.
5. Boucher, H.W., G.H. Talbot, J.S. Bradley, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48: 1-12.
6. Gilbert, D.N., R.J. Guidos, H.W. Boucher, et al. 2010. The 10 x '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50: 1081-1083.
7. World Health Organization. 2005. Containing antimicrobial resistance. WHO Policy Perspectives on Medicines, Geneva, No. 10. Available at: http://whqlibdoc.who.int/hq/2005/WHO_PSM_2005.1.pdf. Accessed 1 July 2012.
8. European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency (EMEA). 2009. ECDC/EMEA Joint Technical Report-The bacterial challenge: time to react. Available at:http://www.emea.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf. Accessed 1 July 2012.
9. Transatlantic Taskforce on Antimicrobial Resistance. 2011. Recommendations for future collaboration between the U.S. and EU. Available at: http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/TATFAR/Documents/210911_TATFAR_Report.pdf. Accessed 1 July 2012.
10. Pew Health Group. 2012. Antibiotic innovation: the threat and the pipeline (Antibiotics and Innovation Project). Available at: http://www.pewhealth.org/reports-analysis/issue-briefs/antibiotic-innovation-the-threat-and-the-pipeline-85899379645. Accessed July 1, 2012.
11. Walton, A.G. 2012. Gonorrhea superbug warning: it's antibiotic resistant and a global public health threat. Forbes Magazine. Available at: http://www.forbes.com/sites/alicegwalton/2012/06/07/gonorrhea-superbug-warning-its-antibiotic-resistant-and-a-global-public-health-threat/. Accessed July 1, 2012.
12. Reinberg, S. 2012. Rare drug-resistant bacteria spotted in U.S. hospital. Swift treatment, stronger infection control prevented spread. US News and World Report. Available at: http://health.usnews.com/health-news/news/articles/2012/06/21/rare-drug-resistant-bacteria-spotted-in-us-hospital. Accessed July 1, 2012.
13. Livermore, D.M. 2009. Has the era of untreatable infections arrived J. Antimicrob. Chemother. 64(Suppl. 1): i29-i36.
14. Souli, M., I. Galani & H. Giamarellou 2008. Emergence of extensively drug-resistant and pandrug-resistant gram-negative bacilli in Europe. Eur. Surveill. 13: 584-593.
15. Hidron, A.I., J.R. Edwards, J. Patel, et al. 2008. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29: 996-1011.
16. Arias, C.A. & B.E. Murray 2009. Antibiotic-resistant bugs in the 21st century-A clinical super-challenge. N. Engl. J. Med. 360: 439-443.
17. Chambers, H.F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10: 781-791.
18. Davies, T.A., R.K. Flamm & A.S. Lynch 2012. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int. J. Antimicrob. Agents 39: 534-538.
19. Peleg, A. Y. & D.C. Hooper 2010. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 362: 1804-1813.
20. Drawz, S.M. & R.A. Bonomo 2010. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23: 160-201.
21. Centers for Disease Control and Prevention. 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR 60: 873-877.
22. Ohnishi M., T. Saika, S. Hoshina, et al. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg. Infect. Dis. 17: 148-149.
23. Bush, K., G.A. Jacoby & A.A. Medeiros 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39: 1211-1233.
24. Jacoby, G.A. & L.S. Munoz-Price 2005. Mechanisms of disease: the new β-lactamases. N. Engl. J. Med. 352: 380-391.
25. Bush, K. & G.A. Jacoby 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54: 969-976.
26. Bush, K. 2010. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 13: 558-564.
27. Canton, R. & T. Coque 2006. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 9: 466-475.
28. Cantón, R., J.M. González-Alba & J.C. Galán 2012. CTX-M enzymes: origin and diffusion. Front. Microbiol. 3: 1-19.
29. Pitout, J.D. & K.B. Laupland 2008. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8: 159-166.
30. Bouchillon, S., M. Hackel, B. Johnson, et al. 2012. Extended-spectrum β-lactamase (ESBL) in vitro activity in urinary tract infections-European TEST program results, 2004-2011. C2-147. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, San Francisco, CA, USA
31. Lewis, J, M. Herrera, B. Wickes, et al. 2007. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 51: 4015-4021.
32. Freeman, J.T., D.J. Sexton & D.J. Anderson 2009. Emergence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States Clin. Infect. Dis. 49: e30-e32.
33. Sanchez, G.V., R.N. Master, J.A. Karlowsky & J.M. Bordon 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob. Agents Chemother. 56: 2181-2183.
34. Park, Y.S., J.M. Adams-Haduch & K.A. Shutt, et al. 2012. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob. Agents Chemother. 56: 1870-1876.
35. Johnson, J.R., C. Urban, S.J. Weissman, et al. 2012. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25: H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob. Agents Chemother. 56: 2364-2370.
36. Tiruvury, H.T., J.R. Johnson, N. Mariano, et al. 2012. Identification of CTX-M β-lactamases among Escherichia coli from the community in New York City. Diagn. Microbiol. Infect. Dis. 72: 248-252.
37. Poirel, L., A. Potron, C. De La Cuesta, et al. 2012. Wild coastline birds as reservoirs of broad-spectrum-β-lactamase-producing Enterobacteriaceae in Miami Beach, Florida. Antimicrob. Agents Chemother. 56: 2756-2758.
38. Shaheen, B.W., R. Nayak & S.L. Foley 2011. Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States. Antimicrob. Agents Chemother. 55: 5666-5675.
39. Tamang, M.D., H-M. Nam, G-C. Jang, et al. 2012. Molecular characterization of extended-spectrum-β-lactamase-producing and plasmid-mediated AmpC β-lactamase-producing Escherichia coli isolated from stray dogs in South Korea. Antimicrob. Agents Chemother. 56: 2705-2712.
40. Rodríguez-Baño, J., M.D. Navarro, L. Romero, et al. 2006. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43: 1407-1414.
41. Lowe, C.F., A. McGeer & M.P. Muller 2012. Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrob. Agents Chemother. 56: 3977-3980.
42. Cornaglia, G., H. Giamarellou & G.M. Rossolini 2011. Metallo-β-lactamases: a last frontier for β-lactams Lancet Infect. Dis. 11: 381-93.
43. Fritsche, T.R., H.S. Sader, M.A. Toleman, et al. 2005. Emerging metallo-β-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 41(Suppl 4): S276-S278.
44. Kumarasamy, K.K., M.A. Toleman, T.R. Walsh, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10: 597-602.
45. Centers for Disease Control and Prevention. 2010. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States. MMWR 59: 749-750.
46. Centers for Disease Control and Prevention. 2012. Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients-Rhode Island. MMWR 61: 446-448.
47. Giskea, C.G., I. Fröding, & C.M. Hasan, et al. 2012. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob. Agents Chemother. 56: 2735-2738.
48. Dantes, R. & A. Guh 2012. Carbapenem-resistant Enterobacteriaceae infection: new guidelines. Available at: http://www.medscape.com/viewarticle/765966. Accessed July 5, 2012
49. Hamburg, M.A., Commissioner of Food and Drug Administration. 2012. Remarks at the National Press Club Speaker Luncheon. Available at: http://www.fda.gov/NewsEvents/Speeches/ucm229195.htm. Accessed July 2, 2012.
50. US Food and Drug Administration. New FDA task force will support innovation in antibacterial drug development. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm. Accessed September 27, 2012
51. Clinical Trials Transformation Initiative. 2012. Available at: https://www.ctti-clinicaltrials.org/. Accessed September 27, 2012.
52. Brookings Institution. 2012. Brookings Council on Antibacterial Drug Development Meeting #1. Available at: http://www.brookings.edu/events/2012/08/30-antibacterial-drug-development. Accessed September 27, 2012.
53. Talbot, G.H., J.H. Powers, T.R. Fleming, et al. 2012. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55: 1114-1121.
54. Pew Health Group. 2012. Bill summary: the Generating Antibiotic Incentives Now Act (H.R. 2182). Available at: http://www.pewtrusts.org/news_room_detail.aspx?id=85899364156. Accessed July 2, 2012.
55. Tamma, P.D. & S.E. Cosgrove 2011. Antimicrobial stewardship. Infect. Dis. Clin. N.A. 25: 245-260.
56. Perez, F., R.A. Salata & R.A. Bonomo 2008. Current and novel antibiotics against resistant gram-positive bacteria. Infect Drug Resist. 1: 27-44.
57. Jones, M.E. 2007. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13(Suppl 2): 17-24.
58. Flamm, R.K., H.S. Sader, D.J. Farrell & R.N. Jones 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the assessing worldwide antimicrobial resistance evaluation (AWARE) surveillance program. Antimicrob. Agents Chemother. 56: 2933-2940.
59. Noel, G.J., K. Bush, P. Bagchi, et al. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46: 647-655.
60. Corey, G.R., M. Wilcox, G.H. Talbot, et al 2010. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51: 641-650.
61. Butler, MS. & M.A. Cooper 2011. Antibiotics in the clinical pipeline in 2011. J. Antibiot 64: 413-425.
62. Bush, K. & M.J. Pucci 2011. New antimicrobial agents on the horizon. Biochem. Pharmacol. 82: 1528-1539.
63. Bassetti, M., F. Ginocchio, M. Mikulska, et al. 2011. Will new antimicrobials overcome resistance among Gram-negatives Expert Rev. Anti-infect. Ther. 9: 909-922.
64. Boucher, H., D. Gilbert, D. Benjamin, et al. 2011. 10 x '20 Progress: development of new drugs active against resistant gram-negative bacilli. Poster LB-27. 49th Annual Meeting of the Infectious Diseases Society of America and the HIV Medicine Association. Boston, Massachusetts, 20-23, October.
65. Jernigan, M.G., E.G. Press, M.H. Nguyen, et al. 2012. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 56: 3395-3398.
66. Lampri, N., I. Galani, G. Poulakou, et al. 2012. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J. Antimicrob. Chemother. 67: 2424-2428.
67. Pallett A. & K. Hand 2010. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J. Antimicrob. Chemother. 65(Suppl 3): iii25-iii33.
68. Castanheira, M., H.S. Sader, D.J. Farrell, et al. 2012. Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56: 4779-4785.
69. Louie, A., M. Castanheira, W. Liu, et al. 2012. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob. Agents Chemother. 56: 258-270.
70. Levasseur, P., A.-M. Girard & M. Claudon 2012. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56: 1606-1608.
71. Ge, Y., M.J. Whitehouse, I. Friedland & G.H. Talbot 2010. Pharmacokinetics (PK) and safety of CXA-101, a new anti-pseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54: 3427-3431.
72. Hirsch, E.B., K.R. Ledesma, K.T. Chang, et al. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 56: 3753-3757.
73. Lagacé-Wiens, P., P. Simner, F. Tailor, et al. 2011. Activity of ceftazidime (CAZ)/NXL104 (CAZ104) versus CAZ alone and other comparators against 4548 gram-negative bacilli-Results from CANWARD 2009-2010. E-1816. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011, Chicago, IL, USA
74. Karlowsky, J., A. Walkty, M. Baxter, et al. 2012. In vitro activity of ceftaroline-avibactam against frequently isolated bacterial pathogens from patients in Canadian hospitals. E-191. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
75. Vazquez, J., L. González Patzán, D. Stricklin, et al. 2012. Ceftazidime avibactam (ceftazidime/NXL104) versus imipenem cilastatin for complicated urinary tract infections in hospitalized adults. L2-909. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
76. Moyá, B., L. Zamorano, C. Juan, et al. 2010. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54: 3933-3937. Published online.
77. Livermore, D. M., S. Mushtaq, Y. Ge & M. Wagner 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34: 402-406.
78. Juan, C., L. Zamorano, J. Peŕrez, et al. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54: 846-851.
79. Zhanel, G. G., H. Adam, A. Walkty, et al. 2012. In vitro activity of ceftolozane/tazobactam tested against 1, 705 gram-negative pathogens isolated from patients in Canadian hospitals in 2011: CANWARD surveillance study. E-200. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
80. Young, K., M. Hackel, C. Lascols, et al. 2012. Response to imipenem plus MK-7655, a novel β-lactamase inhibitor, in a surveillance study population of P. aeruginosa from SMART 2009. C2-724. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
81. Livermore, D. M., M. Warner & S. Mushtaq 2012. Activity of MK-7655 with imipenem vs. β-lactamase producers. E-192. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
82. Page, M.G.P, C. Dantier, E. Desarbre, et al. 2011. In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against gram-negative bacilli that express multiple β-lactamases. Antimicrob. Agents Chemother. 55: 1510-1519.
83. Basilea Pharmaceutica. 2012. Pipeline. Available at: http://www.basilea.com/Development/Pipeline./ Accessed July 28, 2012.
84. Page, M.G., C. Dantier & E. Desarbre 2010. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob. Agents Chemother. 54: 2291-2302.
85. Schmitt-Hoffmann, A., B. Roos, J. Maares, et al. 2011. Pharmacokinetics and safety of the novel sulfactam antibiotic BAL30072 after single ascending dose infusions in healthy volunteers. A2-572. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC, September 17-20, Chicago, IL, USA
86. Rhomberg, P.R., K.A. Fedler, R.K. Flamm, et al. 2012. Antimicrobial activity of BAL30072, alone and in combination with meropenem tested against gram-negative bacteria causing serious infections in hospitals from China, India, Latin America and South East Asia-Pacific. E-193. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012 San Francisco, CA, USA
87. Hecker, S.J., K.R. Reddy, M. Totrov, et al. 2012. Discovery of RPX7009, a broad-spectrum beta-lactamase inhibitor with utility vs. class A serine carbapenemases. F-848. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012 San Francisco, CA, USA
88. Lomovskaya, O., P. King, D. Sun, et al. 2012. Microbiological characterization of beta-lactamase inhibitor RPX7009. F-850. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012, San Francisco, CA, USA
89. Anacor Pharmaceuticals announces that its partner GSK has voluntarily paused enrollment of ongoing GSK '052 phase 1 and 2 clinical trials. [press release]. 2012. Available at: http://www.anacor.com/gsk052.php. Accessed 5 July 2012.
90. Korczak, B. & R. Scott 2012. In vitro activity profile of PMX-30063 against recent clinical isolates of gram-positive and gram-negative pathogens. Available at: http://files.shareholder.com/downloads/ABEA-4ITCYZ/1730124406x0x492675/7e5d6f23-496d-472b-9052-ac057a054a8d/ECCMID_2011-Gram_Pos_Neg_Activity.pdf. Accessed July 5, 2012.
91. Korczak, B. & E. McAllister 2011. A Phase 1 trial to evaluate the tolerability, safety and pharmacokinetics of multi-dose intravenous regimens of PMX-30063. P-1515. 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) May 7-10, 2011 Milan, Italy
92. Jorgensen D., R. Scott, R. Echols & B. Korczak 2012. A phase 2 randomized, double-blinded, dose-ranging, active controlled efficacy and safety evaluation of Brilacidin (PMX-30063) for the treatment of acute skin & skin structure infections (absssi) caused by Staphylococcus aureus (SA). L1-1662. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 9-12, 2012 San Francisco, CA, USA